SCHEMBL24252789

SCHEMBL24252789

Clc1ccc(OC2CCOCC2)c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.44
NPC1 O15118 2/20 0.42
CHEK1 O14757 1/20 0.42
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
NR1I2 O75469 1/20 0.39
HSD11B1 P28845 1/20 0.39
PDE4D Q08499 3/20 0.39
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
KAT2B Q92831 1/20 0.38
BAZ2B Q9UIF8 1/20 0.38
CACNB4 O00305 1/20 0.38
CACNA1A O00555 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25310440 0.88 NPC1 (0.47) NPC1KDM4EMEN1ALDH1A1LMNA
SCHEMBL30467770 0.85 NPC1 (0.46) NPC1KDM4EMEN1ALDH1A1LMNA
SCHEMBL24252931 0.85 NPC1 (0.46) NPC1KDM4EMEN1ALDH1A1LMNA
SCHEMBL19175446 0.81 SYK (0.44) SYKCHEK1KDM4EMEN1ALDH1A1
SCHEMBL21191007 0.81 SYK (0.44) SYKKDM4EPDE4DPDE4APDE4B
SCHEMBL21190864 0.78 SYK (0.43) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL21190866 0.78 IKBKE (0.46) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL739389 0.77 SYK (0.48) SYKNPC1KDM4EALDH1A1LMNA
SCHEMBL275979 0.77 CHEK1 (0.42) SYKCHEK1MEN1KMT2ANR1I2
SCHEMBL21190865 0.77 SYK (0.42) SYKKDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SYK 1943/4885NPC1 460/4885CHEK1 3211/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SYK 1943/4885NPC1 460/4885CHEK1 3211/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SYK 1943/4885NPC1 460/4885CHEK1 3211/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH SYK 1405/4885NPC1 4343/4885CHEK1 703/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 SYK 1143/4885NPC1 1839/4885CHEK1 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.